Printer Friendly

Centers for Disease Control and Prevention updates guidelines for HIV testing.

M2 PHARMA-August 8, 2014-Centers for Disease Control and Prevention updates guidelines for HIV testing

(C)2014 M2 COMMUNICATIONS

8 August 2014 - The Centers for Disease Control and Prevention (CDC), the national public health institute of the USA, has recently updated its guidelines for HIV testing, on the basis of data reviewed by both CDC and the Association of Public Health Laboratories.

The new guidelines recommend that initial testing for HIV should be conducted with an FDA-cleared fourth generation antigen/antibody combination immunoassay identifying HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen to screen for established infection with HIV-1 or HIV-2 and for acute HIV-1 infection. The guidelines require no additional testing for specimens that are non-reactive on the initial immunoassay.

Furthermore, any specimens that have a reactive or repeatedly reactive antigen/antibody combination immunoassay finding should be analysed with an FDA-authorised antibody immunoassay that distinguishes HIV-1 antibodies and HIV-2 antibodies. Reactive findings on the initial antigen/antibody combination immunoassay and the HIV-1/HIV-2 antibody differentiation immunoassay should be considered as positive for HIV-1 antibodies, HIV-2 antibodies, or HIV-1 and HIV-2 antibodies, undifferentiated.

The new guidelines also recommend that any specimens shown as reactive by the first antigen/antibody combination immunoassay and as non-reactive or indeterminate on the HIV-1/HIV-2 antibody differentiation immunoassay, should then be analysed with an FDA-cleared HIV-1 NAT.

The guidelines further recommend that labs should apply this same testing algorithm, starting with a lab-based antigen/antibody combination immunoassay, to serum or plasma specimens filed for testing following a reactive (preliminary positive) finding from any rapid HIV test.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 8, 2014
Words:271
Previous Article:Study shows overexpression of GOLPH3 may be prognostic biomarker in pancreatic ductal adenocarcinoma.
Next Article:Leica Biosystems, Bristol-Myers Squibb to co-develop companion diagnostics for targeted cancer therapeutics.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters